risky

AbbVie’s $8.7 billion bet on Cerevel is risky but smart, analysts say

By Bhanvi Satija and Khushi Mandowara (Reuters) – AbbVie’s decision to buy Cerevel Therapeutics before key data on the drug developer’s experimental schizophrenia treatment may have helped it avoid a potential bidding…

AbbVie’s $8.7 billion bet on Cerevel is risky but smart, analysts say

Testa Urges State to Stop Jersey City’s Risky Deficit Scheme

U.S. details risky Chinese military aircraft maneuvers over past two years

Mexican president says operations at capital airport ‘very risky’

Aircraft lessors cool on risky markets after $10 billion Russia blow

Too good to be bad, too risky to be good, Fed managing ‘unloved’ economy

Brazil’s risky debtors triple since 2019 – central bank

Analysis-Biden hints at risky policy shift on Taiwan independence

Wood’s ARK fund on track for first monthly gain since Oct as risky stocks rally

Analysis-Meme stock investors place risky bet on bankrupt Revlon being the next Hertz

How crypto lender Celsius stumbled on risky bank-like investments

Analysis-Retail traders splurge on risky plays, fueling bounce